FAMPYRA (fampridine), voltage-dependent potassium channel blocker

Low clinical benefit in the management of walking disorders in multiple sclerosis patients

• FAMPYRA has been granted a marketing authorisation for the improvement in walking ability of patients suffering from multiple sclerosis (MS) and presenting with a walking handicap (EDSS 4-7).

• The data derived from a new phase III study have confirmed its modest efficacy versus placebo on walking ability, along with the existence of a small fraction of responders that cannot be identified beforehand.

• Its tolerance profile is marked by high, though relatively infrequent risks of convulsions, severe hypersensitivity and urinary tract infection.

• It failed to improve the quality of life of the patients in the clinical studies.